Tags

Type your tag names separated by a space and hit enter

Tiotropium/Olodaterol: A Review in COPD.
Drugs 2019; 79(9):997-1008D

Abstract

Tiotropium/olodaterol (Stiolto® Respimat®; Spiolto® Respimat®) is an inhaled fixed-dose combination of the long-acting muscarinic antagonist tiotropium bromide (hereafter referred to as tiotropium) and the long-acting β2-adrenergic agonist olodaterol. It is available in several countries, including the USA, Japan, China and those of the EU, where it is indicated for the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The efficacy of tiotropium/olodaterol 5/5 μg/day in patients with COPD was evaluated in phase III or IV trials of 6-52 weeks' duration. Tiotropium/olodaterol improved lung function to a greater extent than each of its individual components or placebo in 12- and 52-week trials. In 6-week trials, tiotropium/olodaterol provided greater lung function benefits over 24 h than the individual components, placebo or twice-daily fluticasone propionate/salmeterol. Tiotropium/olodaterol also demonstrated beneficial effects on health-related quality of life (HR-QoL), dyspnoea, inspiratory capacity, exercise endurance and the need for rescue medication. In an 8-week open-label trial, umeclidinium/vilanterol was superior to tiotropium/olodaterol for the primary endpoint of trough forced expiratory volume in 1 s. The tolerability profile of tiotropium/olodaterol was generally similar to that of the individual components. In conclusion, tiotropium/olodaterol provides a useful option for the maintenance treatment of COPD, with the convenience of once-daily administration via a single inhaler.

Authors+Show Affiliations

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31119643

Citation

Blair, Hannah A.. "Tiotropium/Olodaterol: a Review in COPD." Drugs, vol. 79, no. 9, 2019, pp. 997-1008.
Blair HA. Tiotropium/Olodaterol: A Review in COPD. Drugs. 2019;79(9):997-1008.
Blair, H. A. (2019). Tiotropium/Olodaterol: A Review in COPD. Drugs, 79(9), pp. 997-1008. doi:10.1007/s40265-019-01133-w.
Blair HA. Tiotropium/Olodaterol: a Review in COPD. Drugs. 2019;79(9):997-1008. PubMed PMID: 31119643.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tiotropium/Olodaterol: A Review in COPD. A1 - Blair,Hannah A, PY - 2019/5/24/pubmed PY - 2019/5/24/medline PY - 2019/5/24/entrez SP - 997 EP - 1008 JF - Drugs JO - Drugs VL - 79 IS - 9 N2 - Tiotropium/olodaterol (Stiolto® Respimat®; Spiolto® Respimat®) is an inhaled fixed-dose combination of the long-acting muscarinic antagonist tiotropium bromide (hereafter referred to as tiotropium) and the long-acting β2-adrenergic agonist olodaterol. It is available in several countries, including the USA, Japan, China and those of the EU, where it is indicated for the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The efficacy of tiotropium/olodaterol 5/5 μg/day in patients with COPD was evaluated in phase III or IV trials of 6-52 weeks' duration. Tiotropium/olodaterol improved lung function to a greater extent than each of its individual components or placebo in 12- and 52-week trials. In 6-week trials, tiotropium/olodaterol provided greater lung function benefits over 24 h than the individual components, placebo or twice-daily fluticasone propionate/salmeterol. Tiotropium/olodaterol also demonstrated beneficial effects on health-related quality of life (HR-QoL), dyspnoea, inspiratory capacity, exercise endurance and the need for rescue medication. In an 8-week open-label trial, umeclidinium/vilanterol was superior to tiotropium/olodaterol for the primary endpoint of trough forced expiratory volume in 1 s. The tolerability profile of tiotropium/olodaterol was generally similar to that of the individual components. In conclusion, tiotropium/olodaterol provides a useful option for the maintenance treatment of COPD, with the convenience of once-daily administration via a single inhaler. SN - 1179-1950 UR - https://www.unboundmedicine.com/medline/citation/31119643/Tiotropium/Olodaterol:_A_Review_in_COPD L2 - https://dx.doi.org/10.1007/s40265-019-01133-w DB - PRIME DP - Unbound Medicine ER -